AbstractThe recognition that the enzyme hydrogen-potassium-ATPase (H-K-ATPase) was involved in the final step of acid secretion culminated in the development of a class of drugs called the proton pump inhibitors (PPIs), which are targeted at inhibiting this enzyme.1 The PPIs are the most potent inhibitors of gastric secretion available.1 They are most effective when the parietal cell is stimulated to secrete acid postprandially, a relationship that has important clinical implications for timing of administration.1 Since the amount of H-K-ATPase present in the parietal cell is greatest after a prolonged fast, PPIs should be administered before the first meal of the day.1 Omeprazole was the first PPI to become available clinically.1 It is currently available as 10 mg, 20 mg and 40 mg MUPS tablets, as 10 mg, 20 mg and 40 mg capsules and as a 40 mg/vial intravenous infusion.
Focus on ...
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.